Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meriggioli, M.N.
Right arrow Articles by Sanders, D.B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meriggioli, M.N.
Right arrow Articles by Sanders, D.B.
Related Collections
Right arrow Myasthenia
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2003;61:1438-1440
© 2003 American Academy of Neurology
Brief Communications

Mycophenolate mofetil for myasthenia gravis

An analysis of efficacy, safety, and tolerability

M.N. Meriggioli, MD*, E. Ciafaloni, MD*, K.A. Al-Hayk, MD, J. Rowin, MD, B. Tucker-Lipscomb, RN, J.M. Massey, MD and D.B. Sanders, MD

From the Department of Neurological Sciences (Drs. Meriggioli and Rowin), Rush University, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, IL; the Department of Neurology (Dr. Ciafaloni), University of Rochester School of Medicine, NY; and the Division of Neurology (Drs. Al-Hayk, Massey, and Sanders, and B. Tucker-Lipscomb), Duke University Medical Center, Durham, NC.

Address correspondence and reprint requests to Dr. Matthew N. Meriggioli, Rush University, Dept. of Neurological Sciences, 1725 W. Harrison Street, Suite 1106, Chicago, IL 60612; e-mail: Matthew_N_Meriggioli{at}rush.edu

The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.

Received May 28, 2003. Accepted in final form July 26, 2003.

*These authors contributed equally to this work.

Presented at the annual meeting of the American Academy of Neurology; April 3, 2003.




This article has been cited by other articles:


Home page
 NeurologyHome page
M. Benatar and L. P. Rowland
The muddle of mycophenolate mofetil in myasthenia
Neurology, August 5, 2008; 71(6): 390 - 391.
[Full Text] [PDF]

Home page
 NeurologyHome page
The Muscle Study Group
A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis
Neurology, August 5, 2008; 71(6): 394 - 399.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. B. Sanders, I. K. Hart, R. Mantegazza, S. S. Shukla, Z. A. Siddiqi, M.H.V. De Baets, A. Melms, M. W. Nicolle, N. Solomons, and D. P. Richman
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
Neurology, August 5, 2008; 71(6): 400 - 406.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
S. Piepers, R. Van den Berg-Vos, W-L. Van der Pol, H. Franssen, J. Wokke, and L. Van den Berg
Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial
Brain, August 1, 2007; 130(8): 2004 - 2010.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
W. D Cahoon Jr and D. R Kockler
Mycophenolate Mofetil Treatment of Myasthenia Gravis
Ann. Pharmacother., February 1, 2006; 40(2): 295 - 298.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Vernino, D. R. Salomao, T. M. Habermann, and B. P. O'Neill
Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil
Neurology, August 23, 2005; 65(4): 639 - 641.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. S. Bedlack, D. L. Simel, H. Bosworth, G. Samsa, B. Tucker-Lipscomb, and D. B. Sanders
Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity
Neurology, June 14, 2005; 64(11): 1968 - 1970.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
E Ciafaloni
Mycophenolate mofetil and myasthenia gravis
Lupus, March 1, 2005; 14(3_suppl): s46 - s49.
[Abstract] [PDF]

Home page
 LupusHome page
E. Ciafaloni
Mycophenolate mofetil and myasthenia gravis
Lupus, January 1, 2005; 14(1_suppl): s46 - s49.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.